Zytiga launched for advanced prostate cancer

Zytiga (abiraterone) is indicated for use in combination with prednisolone to treat metastatic castration-resistant prostate cancer that has progressed during or after docetaxel treatment.

Zytiga is taken once daily
Zytiga is taken once daily

PHARMACOLOGY

By inhibiting CYP17 (17alpha-hydroxylase/C17,20-lyase), abiraterone blocks the synthesis of testosterone in the adrenal glands and testes, as well as in the prostate tumour itself.1

CLINICAL STUDIES

Approval of abiraterone was based on a randomised, double-blind phase 3 trial in 1195 men with metastatic prostate cancer who had previously received docetaxel. In this trial, men who were given abiraterone 1g daily, plus low-dose prednisone or prednisolone, lived for a median of 14.8 months compared with 10.9 months for men taking placebo plus prednisolone or prednisone.1 This difference translated into a 35.4% reduction in the risk of death with abiraterone compared with placebo (95% CI 23–46%; p<0.001).2

The proportion of patients who experienced a 30% reduction in the worst pain intensity was also significantly greater with abiraterone than placebo (44% vs 27%; p=0.0002).

View Zytiga drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases